Share This Author
Advances in understanding the pathogenesis of primary Sjögren's syndrome
Recent findings regarding the pathogenic mechanisms involved in primary Sjögren's syndrome are summarized and lead to the development of promising novel therapeutic strategies.
NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren’s Syndrome
Findings suggest that NK cells may promote an NKp30-dependent inflammatory state in salivary glands and that blockade of the B7H6/NKp30 axis could be clinically relevant in pSS, and put forth NK p30 as a therapeutic target, providing a potential oasis for Sjögren’s patients.
Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Encouraging results justify future randomised controlled trials of belimumab in a selected target population of pSS patients most likely to benefit from treatment.
Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome
To define parameters predictive of lymphoma development in patients with primary Sjögren's syndrome (SS), parameters are defined and histopathological parameters are analyzed.
Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome.
A key role is supported for germline and somatic variations of A20 in the transformation between autoimmunity and lymphoma in patients with primary Sjögren's syndrome and patients with lymphoma.
Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management
Lymphomagenesis associated with pSS exemplifies the development of antigen‐driven B‐cell lymphoma, and new findings allow a better understanding of the pathogenic mechanisms leading to lymphoma.
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
B cells in the pathogenesis of primary Sjögren syndrome
The mechanisms that support the increased activation of B cells in pSS are discussed, including genetic and epigenetic factors and environmental triggers that promote B cell activation via the innate immune system.
CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome
The link between CCL11 and CXCL13 and ectopic GCs, as well as the association between these chemokines and disease activity, in patients with primary Sjögren's syndrome were assessed.
Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS…
In pSS, higher levels of beta2-microglobulin and free light chains of immunoglobulins are associated with increased systemic disease activity.